Neurobehavioral effects in HIV-positive individuals receiving highly active antiretroviral therapy (HAART) in Gaborone, Botswana.

<h4>Objective</h4>To explore the prevalence and features of HIV-associated neurocognitive disorders (HANDS) in Botswana, a sub-Saharan country at the center of the HIV epidemic.<h4>Design and methods</h4>A cross sectional study of 60 HIV-positive individuals, all receiving hi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kathy Lawler, Kealeboga Jeremiah, Mosepele Mosepele, Sarah J Ratcliffe, Catherine Cherry, Esther Seloilwe, Andrew P Steenhoff
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2011
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/72aafc3b2e4744be8625805b993f7770
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:72aafc3b2e4744be8625805b993f7770
record_format	dspace
spelling	oai:doaj.org-article:72aafc3b2e4744be8625805b993f77702021-11-18T06:58:32ZNeurobehavioral effects in HIV-positive individuals receiving highly active antiretroviral therapy (HAART) in Gaborone, Botswana.1932-620310.1371/journal.pone.0017233https://doaj.org/article/72aafc3b2e4744be8625805b993f77702011-02-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21365002/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Objective</h4>To explore the prevalence and features of HIV-associated neurocognitive disorders (HANDS) in Botswana, a sub-Saharan country at the center of the HIV epidemic.<h4>Design and methods</h4>A cross sectional study of 60 HIV-positive individuals, all receiving highly active antiretroviral therapy (HAART), and 80 demographically matched HIV-seronegative control subjects. We administered a comprehensive neuropsychological test battery and structured psychiatric interview. The lowest 10(th) percentile of results achieved by control subjects was used to define the lower limit of normal performance on cognitive measures. Subjects who scored abnormal on three or more measures were classified as cognitively impaired. To determine the clinical significance of any cognitive impairment, we assessed medication adherence, employment, and independence in activities of daily living (ADL).<h4>Results</h4>HIV+ subjects were impaired for all cognitive-motor ability areas compared with matched, uninfected control subjects. Thirty seven percent of HIV+ patients met criteria for cognitive impairment.<h4>Conclusion</h4>These findings indicate that neurocognitive impairment is likely to be an important feature of HIV infection in resource-limited countries; underscoring the need to develop effective treatments for subjects with, or at risk of developing, cognitive impairment.Kathy LawlerKealeboga JeremiahMosepele MosepeleSarah J RatcliffeCatherine CherryEsther SeloilweAndrew P SteenhoffPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 6, Iss 2, p e17233 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Kathy Lawler Kealeboga Jeremiah Mosepele Mosepele Sarah J Ratcliffe Catherine Cherry Esther Seloilwe Andrew P Steenhoff Neurobehavioral effects in HIV-positive individuals receiving highly active antiretroviral therapy (HAART) in Gaborone, Botswana.
description	<h4>Objective</h4>To explore the prevalence and features of HIV-associated neurocognitive disorders (HANDS) in Botswana, a sub-Saharan country at the center of the HIV epidemic.<h4>Design and methods</h4>A cross sectional study of 60 HIV-positive individuals, all receiving highly active antiretroviral therapy (HAART), and 80 demographically matched HIV-seronegative control subjects. We administered a comprehensive neuropsychological test battery and structured psychiatric interview. The lowest 10(th) percentile of results achieved by control subjects was used to define the lower limit of normal performance on cognitive measures. Subjects who scored abnormal on three or more measures were classified as cognitively impaired. To determine the clinical significance of any cognitive impairment, we assessed medication adherence, employment, and independence in activities of daily living (ADL).<h4>Results</h4>HIV+ subjects were impaired for all cognitive-motor ability areas compared with matched, uninfected control subjects. Thirty seven percent of HIV+ patients met criteria for cognitive impairment.<h4>Conclusion</h4>These findings indicate that neurocognitive impairment is likely to be an important feature of HIV infection in resource-limited countries; underscoring the need to develop effective treatments for subjects with, or at risk of developing, cognitive impairment.
format	article
author	Kathy Lawler Kealeboga Jeremiah Mosepele Mosepele Sarah J Ratcliffe Catherine Cherry Esther Seloilwe Andrew P Steenhoff
author_facet	Kathy Lawler Kealeboga Jeremiah Mosepele Mosepele Sarah J Ratcliffe Catherine Cherry Esther Seloilwe Andrew P Steenhoff
author_sort	Kathy Lawler
title	Neurobehavioral effects in HIV-positive individuals receiving highly active antiretroviral therapy (HAART) in Gaborone, Botswana.
title_short	Neurobehavioral effects in HIV-positive individuals receiving highly active antiretroviral therapy (HAART) in Gaborone, Botswana.
title_full	Neurobehavioral effects in HIV-positive individuals receiving highly active antiretroviral therapy (HAART) in Gaborone, Botswana.
title_fullStr	Neurobehavioral effects in HIV-positive individuals receiving highly active antiretroviral therapy (HAART) in Gaborone, Botswana.
title_full_unstemmed	Neurobehavioral effects in HIV-positive individuals receiving highly active antiretroviral therapy (HAART) in Gaborone, Botswana.
title_sort	neurobehavioral effects in hiv-positive individuals receiving highly active antiretroviral therapy (haart) in gaborone, botswana.
publisher	Public Library of Science (PLoS)
publishDate	2011
url	https://doaj.org/article/72aafc3b2e4744be8625805b993f7770
work_keys_str_mv	AT kathylawler neurobehavioraleffectsinhivpositiveindividualsreceivinghighlyactiveantiretroviraltherapyhaartingaboronebotswana AT kealebogajeremiah neurobehavioraleffectsinhivpositiveindividualsreceivinghighlyactiveantiretroviraltherapyhaartingaboronebotswana AT mosepelemosepele neurobehavioraleffectsinhivpositiveindividualsreceivinghighlyactiveantiretroviraltherapyhaartingaboronebotswana AT sarahjratcliffe neurobehavioraleffectsinhivpositiveindividualsreceivinghighlyactiveantiretroviraltherapyhaartingaboronebotswana AT catherinecherry neurobehavioraleffectsinhivpositiveindividualsreceivinghighlyactiveantiretroviraltherapyhaartingaboronebotswana AT estherseloilwe neurobehavioraleffectsinhivpositiveindividualsreceivinghighlyactiveantiretroviraltherapyhaartingaboronebotswana AT andrewpsteenhoff neurobehavioraleffectsinhivpositiveindividualsreceivinghighlyactiveantiretroviraltherapyhaartingaboronebotswana
_version_	1718424109820411904

Neurobehavioral effects in HIV-positive individuals receiving highly active antiretroviral therapy (HAART) in Gaborone, Botswana.

Ejemplares similares